reviewing by of revenue the CF medicines. QX Thank performance I'll you, our Reshma. begin
QX nearly U.S., in in the the XX launch of since the the been regulatory billion, continued ages successful. result strong and the treatment. has patients eligible increasing global U.S. KAFTRIO as approval, driven outside a vast TRIKAFTA $X.X plus Our U.S. And two just of In by highly performance the revenues years of initiated reached majority of revenues launch under have
children approval. focused in reimbursement see the ages to ongoing approval very high Outside We EMA progress of continued XX standard, six persistence in we terms in have significant than more timeline made countries, agreements. U.S., in TRIKAFTA access the the year now in We the XX of This to compliance following the to we're following one for and the markets we countries launch medicines. June. have in reimbursement U.S., both less have with outside the compares levels, number total our U.S., have reimbursed than the and and industry on for of now in individual which favorably KAFTRIO
of over be of the and CF our built progress reimbursement expertise collaboration team, the the rapid clinical attributed community, factors, multiple triple the commercial can combination, to Our of decade. transformative of the a and course benefits the governments support and
therapy the performance to the fully are all studies TRIKAFTA earlier, benefits Reshma as the levels be of continuing long-term clinical our medicines prior were to pivotal able the communicate clinical are pivotal in considerable real our recognize medicines, CFTR long-term of modulators track for achieving mentioned to value. The and key world, and extension our in trials Importantly, of And stakeholders. we we for as combination data that triple of all with to their reimbursement at trial unprecedented. understand
label time. CFTR system that the We treated of main disease lung data previously TRIKAFTA of forum. This forward results function FF is long-term combination. treatment of CF follow-up we the month, with extension sharing slows have data for and do a We at patients. pivotal our benefits FMF in powerful in Earlier XX-weeks any course decline decline, SYMDEKO over ORKAMBI and evidence a least look function the this in forthcoming any KALYDECO, with see trials, transforms we in these in In first clinical the open lung not patient medical with and obtained the multi populations first to shown our triple the modulators. for
to go a way CF reach far, Although, we achieved to all still pleased patients. are what have with so we've long we
remain from communicated, living And and previously have likely to approximately benefit we these people I Canada, we U.S., we CTXXXX. medicines of able confident late with we are launching agreements reimbursement, our perspective there modulator. expansions XX% additional we are the estimate vast CF where successfully As younger in CFTR our pipeline. significant groups. provide there now by that Europe treated. label a of have securing market which reimbursement Australia. are and the to of achieved some medicines, will Reaching growth these mid And majority patients be patients could are to not estimate these revenue reach We more CF will drive benefit would be current to age opportunities who medicines who stage from patients. will our XX,XXX additional Starting the with and yet like for than being XX,XXX some in on other the new
amendment collaboration With leadership CRISPR aspects global taken of CTXXXX agreement program. the our for has the of with Therapeutics, all now Vertex
medicines. in result, the a beta patients develop we leverage XXX,XXX for curative Europe, XX,XXX We access of be CTXXXX. disease, to the transformative in with research, disease And and a holds sickle the with surveys the sickle U.S. an of highly Vertex’s see demonstrated which using cell physicians than are they good is the have of of disease quarter severe one-time valued attractive that disease to with for market in severe be by tremendous their U.S. the We who that regimens cell the XX,XXX indicate approach conditioning gentler candidates the editing there own beta sickle to more are a a XXX,XXX, of severe payers. and patients, numbers the for regimen, estimates line U.S. sickle internal thalassemia, vast approach or and potential estimate majority We a in and of As conditioning larger future, proportion patients which are approximately for ability curative CTXXXX third to and we position much patients. have cell expect treatment our expect in reimbursement consistently that patients. for gene a in a thalassemia, potential Consistent published current these the be option are whom patients, disease. one-time physician will cell a and secure believe would
one, guiding significant cell are symptomatic features efforts lifelong number disease have history cost burdens. market, underway. pre-commercial patients are and hospitalizations to Our of sickle including well this that are with and severe a other our thalassemia a of and are There approach notable beta
economic cure payment health for are be new the for Two, and cost effectiveness We cure these demonstrate flexible functional functional developing a patients. models for of a these will diseases. to needed models
and are geographically with to understand engaged them, what And concentrated. for payers are for patients. We work three, best patients models
instance, eligible sickle in in For XX U.S. cell XX% the states. of patients live
to and both We insights and that other establish effective will use as is in these lean highly have commercial a we CF today. operation
the me the medicine new multibillion market now efficacy, current Let novel of significant billion has their without in of even pain, days X.X the our medicine of addictive prescriptions a underscoring acute all than within the and hospital pain A share to more would is be post-operative market, therapies a opportunity limitations of regards transformative Acute the settings. a being pain, medicine acute prescriptions. the XX% dollar account perspective of to patients XX% treatment opportunity U.S. healthcare for With takes area. Despite U.S. transformative represent commercialization, and In market with opioids. a billion potential. opioids, of opioid the a potential represents in and turn portion component highly still system. this A $X hospitals a for is for novel days generic, high treatment concentrated on particularly treatment for that XX% year agent. pain and
possible our with SG&A model, focused small approach. successful commercialization lean specialist commercial with Given this consistent concentration, again, be will a
transplant Finally, diabetes, to the in clinical patient type XX,XXX a VX-XXX. type We X transformative and itself, begin VX-XXX program diabetes we prior a transplant alone with severe and therapy. establish the the advanced and of X with islet high diabetes relatively market potential have for will significant candidates that existing Europe a cells profile. a studies opportunity. a view type or kidney of basis approaches would In be has its soon estimate X patients is U.S. for And value
could CF the pipeline it's Europe. Beyond Charlie. the at to And beyond time address patients. label our transform program million to late significant and presenting to X we each I'll in in broader patients still In we more expansions to Vertex hand VX-XXX the both age continue cells younger potential type conclusion, reimbursement device is with and CF, And it having as mid new an and lives be to with and X.X agreements our growth medicines population, program exciting CF, commercial groups. have diabetes a U.S. bring and stage over opportunity. rapidly advancing that, to the significant And ahead with
